AIM, ImmunoTech

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline

Published on 02/11/2026 at 11:13 | Redaktion boerse-global.de

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm announced the commencement of a rights offering today, coinciding with an investor webinar. The central question for stakeholders is whether the targeted capital will be sufficient to advance the company’s lead drug candidate, Ampligen, through its ambitious trial objectives.

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline Illustration mit AI erstellt übermittelt durch boerse-global.de
AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline Illustration mit AI erstellt übermittelt durch boerse-global.de

Concurrently with the offering, company management is hosting a conference to update investors on clinical progress, particularly for the DURIPANC Phase 2 study. This trial is evaluating Ampligen in combination with AstraZeneca’s immunotherapy drug, Imfinzi, as a treatment for metastatic pancreatic cancer.

Key Clinical Trial Status:
* Patient Recruitment: 18 out of a planned 25 patients have Read more...

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | US00901B1052 | AIM | boerse | 68572103 |